MedTrace Logo

Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease

NCT04569825 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2020-09-30

No results posted yet for this study

Summary

Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy. However, the effect of local steroid was not assessed before.

Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients.

Conditions

  • Clinical Trial

Interventions

DRUG

Ophtamesone

local application intranasally as drops

Sponsors & Collaborators

  • University Of Anbar

    lead OTHER

Principal Investigators

  • Raid M Al-Ani, FIBMS (ENT) · University Of Anbar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-09-30
Completion
2020-10-15

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569825 on ClinicalTrials.gov